# Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer

> **NCT07425795** · PHASE2 · RECRUITING · sponsor: **Chongqing University Cancer Hospital** · enrollment: 36 (estimated)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer (ES-SCLC)

## Interventions

- **DRUG:** Tislelizumab Combined With Chemotherapy

## Key facts

- **NCT ID:** NCT07425795
- **Lead sponsor:** Chongqing University Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-10
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07425795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07425795, "Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07425795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*